Table 1.

Unadjusted and Adjusted Cox Model Estimates for Risk of Epstein-Barr Virus Acquisition

Covariate	Unadjusted HR (95% CI)	P Value	Adjusted HRa (95% CI)	P Value
gp350 binding antibody per log10 increase	1.4 (.6–3.2)	.417	1.0 (.4–2.5)	.945
gH/gL binding antibody per log10 increase	2.0 (.7–5.7)	.182	1.2 (.4–3.5)	.704
B-cell neutralization IC50 per log10 increase	3.0 (1.3–7.0)	.012	1.2 (.4–3.2)	.734
Epithelial-cell neutralization per log10 increase	1.02 (1.00–1.04)	.019	1.02 (1.00–1.03)	.100
gp350 ADCC CD107a+ % per 1-unit increase
0–6 mo	0.03 (.0–6.9)	.209	0.1 (.0–8.6)	.279
>6 mo	1.3 (1.1–1.6)	.004	1.2 (1.0–1.4)	.086
gH/gL ADCC CD107a+ % per 1-unit increase
0–6 mo	0.5 (.0–6.6)	.596	0.3 (.0–8.2)	.488
>6 mo	1.9 (.8–4.5)	.158	2.4 (.9–6.7)	.096

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CI, confidence interval; HR, hazard ratio; IC₅₀, 50% inhibitory concentration.

^aMultivariate analysis adjusted for maternal HIV status.